567 related articles for article (PubMed ID: 16784976)
1. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
2. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Moriya T
J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
[TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
4. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns.
Boecker W; Buerger H; Schmitz K; Ellis IA; van Diest PJ; Sinn HP; Geradts J; Diallo R; Poremba C; Herbst H
J Pathol; 2001 Nov; 195(4):415-21. PubMed ID: 11745672
[TBL] [Abstract][Full Text] [Related]
5. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor.
Xu S; Wei B; Zhang H; Qing M; Bu H
Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions.
Tan PH; Lui GG; Chiang G; Yap WM; Poh WT; Bay BH
Histopathology; 2004 Oct; 45(4):343-51. PubMed ID: 15469472
[TBL] [Abstract][Full Text] [Related]
7. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms.
Raju UB; Lee MW; Zarbo RJ; Crissman JD
Mod Pathol; 1989 Nov; 2(6):569-76. PubMed ID: 2479944
[TBL] [Abstract][Full Text] [Related]
8. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
[TBL] [Abstract][Full Text] [Related]
9. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
10. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T
Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808
[TBL] [Abstract][Full Text] [Related]
11. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis.
Simooka H; Oyama T; Sano T; Horiguchi J; Nakajima T
Pathol Int; 2004 Aug; 54(8):595-602. PubMed ID: 15260850
[TBL] [Abstract][Full Text] [Related]
13. Nipple aspirate fluid cytology in breast carcinoma.
Krishnamurthy S; Sneige N; Thompson PA; Marcy SM; Singletary SE; Cristofanilli M; Hunt KK; Kuerer HM
Cancer; 2003 Apr; 99(2):97-104. PubMed ID: 12704689
[TBL] [Abstract][Full Text] [Related]
14. Utility of cytokeratin 5/6 and high-molecular-weight keratin in evaluation of cauterized surgical margins in excised specimens of breast ductal carcinoma in situ.
Nayak A; Bhuiya TA
Ann Diagn Pathol; 2011 Aug; 15(4):243-9. PubMed ID: 21420886
[TBL] [Abstract][Full Text] [Related]
15. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
Rabban JT; Chen YY
Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
[TBL] [Abstract][Full Text] [Related]
17. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
[TBL] [Abstract][Full Text] [Related]
18. Nuclear cytometric changes in breast carcinogenesis.
Mommers EC; Poulin N; Sangulin J; Meijer CJ; Baak JP; van Diest PJ
J Pathol; 2001 Jan; 193(1):33-9. PubMed ID: 11169513
[TBL] [Abstract][Full Text] [Related]
19. Artefactual Epithelial Displacement in a Papilloma with Extensive Usual Duct Hyperplasia Mimics a Solid Papillary Carcinoma with Invasive Growth.
François A; Galant C; Berlière M; Van Bockstal MR
Int J Surg Pathol; 2021 Jun; 29(4):395-399. PubMed ID: 33736513
[TBL] [Abstract][Full Text] [Related]
20. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
